HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation

EGF-stimulated activation of Rab35 regulates RUSC2–GIT2 complex formation to stabilize GIT2 during directional lung cancer cell migration

(2016) Biao Duan et al.   CANCER LETTERS

New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer

(2016) Sherry X. Yang et al.   CANCER TREATMENT REVIEWS

Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma

(2016) Matthew H. Wong et al.   NEOPLASIA

Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2

(2015) H. P. Soares et al.   MOLECULAR CANCER THERAPEUTICS

PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition

(2015) Z Meng et al.   ONCOGENE

HDAC6 sustains growth stimulation by prolonging the activation of EGF receptor through the inhibition of rabaptin-5-mediated early endosome fusion in gastric cancer

(2014) Se Jin Park et al.   CANCER LETTERS

Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors

(2014) Ozgur Sahin et al.   CELL RESEARCH

HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer

(2014) Si-Meng Chen et al.   INTERNATIONAL JOURNAL OF CANCER

Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast

(2014) Jinwon Seo et al.   Journal of Breast Cancer

Drugging the HDAC6–HSP90 interplay in malignant cells

(2014) Oliver H. Krämer et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

HDAC6 Inhibition Restores Ciliary Expression and Decreases Tumor Growth

(2013) S. A. Gradilone et al.   CANCER RESEARCH

PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer

(2013) Giovanni Luca Gravina et al.   ENDOCRINE-RELATED CANCER

Association between HSP90 and Her2 in Gastric and Gastroesophageal Carcinomas

(2013) Sabina Berezowska et al.   PLoS One

Microtubules Coordinate VEGFR2 Signaling and Sorting

(2013) Catherine Czeisler et al.   PLoS One

Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer

(2013) M. J. Niederst et al.   Science Signaling

Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells

(2012) Taru Muranen et al.   CANCER CELL

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation

(2011) Yisheng Jiao et al.   Molecular Cancer

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

(2011) V Serra et al.   ONCOGENE

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors

(2011) A. Chakrabarty et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

mTOR Inhibition, the Second Generation: ATP-Competitive mTOR Inhibitor Initiates Unexpected Receptor Tyrosine Kinase-Driven Feedback Loop

(2011) M. Keniry et al.   Cancer Discovery

mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling

(2011) V. S. Rodrik-Outmezguine et al.   Cancer Discovery

The Role of HDAC6 in Cancer

(2010) Grace I. Aldana-Masangkay et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90

(2010) Qingwei Meng et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts

(2009) P Cao et al.   BRITISH JOURNAL OF CANCER

Targeted therapy of metastatic breast cancer

(2009) Alfonso Sánchez-Muñoz et al.   Clinical & Translational Oncology

The upgraded role of HER3 and HER4 receptors in breast cancer

(2009) Angelos K. Koutras et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

(2008) V. Serra et al.   CANCER RESEARCH

Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel

(2008) A. Sawai et al.   CANCER RESEARCH

The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma

(2008) Philipp Baumann et al.   EXPERIMENTAL CELL RESEARCH

Destabilization of ERBB2 Transcripts by Targeting 3' Untranslated Region Messenger RNA Associated HuR and Histone Deacetylase-6

(2008) G. K. Scott et al.   MOLECULAR CANCER RESEARCH

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE

Beyond tamoxifen: Extended and late extended endocrine therapy in postmenopausal early breast cancer

(2007) David Dodwell et al.   CANCER TREATMENT REVIEWS